Article
Genetics & Heredity
Andreas Venizelos, Christina Engebrethsen, Wei Deng, Jurgen Geisler, Stephanie Geisler, Gjertrud T. Iversen, Turid Aas, Hildegunn S. Aase, Manouchehr Seyedzadeh, Eli Sihn Steinskog, Ola Myklebost, Sigve Nakken, Daniel Vodak, Eivind Hovig, Leonardo A. Meza-Zepeda, Per E. Lonning, Stian Knappskog, Hans P. Eikesdal
Summary: Subclonal composition of treatment-naive breast cancers undergoes profound changes during neoadjuvant chemotherapy with epirubicin and docetaxel monotherapy, while early truncal mutations and major subclones generally persist through treatment. Tumor mutational burden decreases during neoadjuvant therapy.
Article
Oncology
Christoph Thomssen, Martina Vetter, Eva J. J. Kantelhardt, Christoph Meisner, Marcus Schmidt, Pierre M. M. Martin, Florian Clatot, Doris Augustin, Volker Hanf, Daniela Paepke, Wolfgang Meinerz, Gerald Hoffmann, Wolfgang Wiest, Fred C. G. J. Sweep, Manfred Schmitt, Fritz Jaenicke, Sibylle Loibl, Gunter von Minckwitz, Nadia Harbeck
Summary: The NNBC-3 Europe trial aimed to assess the risk of recurrence in node-negative breast cancer patients and to determine whether taxanes can improve disease-free survival in high-risk patients. The study found that patients with high-risk node-negative breast cancer have a favorable prognosis in the first few years after diagnosis regardless of the type of chemotherapy.
Article
Oncology
Kerstin Wimmer, Monika Sachet, Cristiano Ramos, Sophie Frantal, Hanna Birnleitner, Christine Brostjan, Ruth Exner, Martin Filipits, Zsuzsanna Bago-Horvath, Margaretha Rudas, Rupert Bartsch, Michael Gnant, Christian F. Singer, Marija Balic, Daniel Egle, Rudolf Oehler, Florian Fitzal
Summary: This study compared the immunomodulatory effects of Epirubicin/cyclophosphamide (EC) and docetaxel (D) in neoadjuvant treatment of breast cancer. The results showed that EC had strong immunosuppressive properties, while D had a supportive effect on the immune system. These findings have important implications for the planning of combination therapies with immunotherapies in breast cancer.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Liulu Zhang, Zhi-Yong Wu, Jie Li, Ying Lin, Zhenzhen Liu, Yin Cao, Gangling Zhang, Hong-Fei Gao, Mei Yang, Ci-Qiu Yang, Teng Zhu, Min-Yi Cheng, Fei Ji, Jieqing Li, Kun Wang
Summary: In a randomized controlled trial, it was found that the addition of carboplatin to neoadjuvant chemotherapy significantly improved the pathologic complete response rate in patients with untreated stage II-III TNBC compared to anthracycline-based regimens. Despite the different treatment protocols, overall survival and event-free survival rates were comparable between the two groups after a 37-month follow-up period.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Houpu Yang, Ling Xu, Shan Guan, Xiaopeng Hao, Zhicheng Ge, Fuzhong Tong, Yingming Cao, Peng Liu, Bo Zhou, Lin Cheng, Miao Liu, Hongjun Liu, Fei Xie, Siyuan Wang, Yuan Peng, Chaobin Wang, Shu Wang
Summary: This study evaluated the efficacy and safety of the combination of docetaxel and capecitabine in the treatment of early breast cancer and compared it with the combination of docetaxel and epirubicin. The results showed comparable rates of pathological complete response and long-term survival between the two treatment regimens, suggesting that the anthracycline-free TX regimen could be considered in selected patients.
Article
Oncology
Deyue Liu, Jiayi Wu, Caijin Lin, Shuning Ding, Shuangshuang Lu, Yan Fang, Jiahui Huang, Jin Hong, Weiqi Gao, Siji Zhu, Xiaosong Chen, Ou Huang, Jianrong He, Weiguo Chen, Yafen Li, Kunwei Shen, Li Zhu
Summary: Anthracycline and taxane-based chemotherapy are commonly used adjuvant therapy for early breast cancer. Removing anthracycline from the treatment regimen is a feasible alternative for HER2-negative breast cancer patients. The ELEGANT trial compared the safety and efficacy of epirubicin and cyclophosphamide (EC) versus docetaxel and cyclophosphamide (TC) and found that the rate of grade 3 or 4 neutropenia is similar between the two regimens, but more adverse events were observed in the EC group.
Article
Cardiac & Cardiovascular Systems
Jessica M. Scott, Jasme Lee, James E. Herndon, Meghan G. Michalski, Catherine P. Lee, Kelly A. O'Brien, John P. Sasso, Anthony F. Yu, Kylie A. Rowed, Jacqueline F. Bromberg, Tiffany A. Traina, Ayca Gucalp, Rachel A. Sanford, Devika Gajria, Shanu Modi, Elisabeth A. Comen, Gabriella D'Andrea, Victoria S. Blinder, Neil D. Eves, Jeffrey M. Peppercorn, Chaya S. Moskowitz, Chau T. Dang, Lee W. Jones
Summary: This study examined the timing of exercise therapy to improve cardiorespiratory fitness (CRF) among breast cancer patients initiating chemotherapy. The results showed that there was no significant difference in CRF improvement between exercise therapy during chemotherapy and exercise therapy after chemotherapy compared to usual care. However, continuous exercise therapy for approximately 32 weeks was associated with significant improvements in CRF. This suggests that continuous exercise therapy may be a promising strategy for improving fitness in breast cancer patients.
EUROPEAN HEART JOURNAL
(2023)
Article
Oncology
Jiahui Huang, Yiwei Tong, Jin Hong, Ou Huang, Jiayi Wu, Jianrong He, Weiguo Chen, Yafen Li, Xiaosong Chen, Kunwei Shen
Summary: This study aimed to evaluate the efficacy, safety, and metabolic parameters change of metformin combined with TEC in neoadjuvant treatment for breast cancer patients with metabolic abnormality. The results showed that adding metformin did not increase the total pathological complete response rate and disease outcome in breast cancer patients, but it could prevent the increase of total cholesterol and low-density lipoprotein cholesterol after treatment.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Heikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, Riikka Huovinen, Arja Jukkola, Minna Tanner, Johan Ahlgren, Paivi Auvinen, Outi Lahdenpera, Kenneth Villman, Paul Nyandoto, Greger Nilsson, Paula Poikonen-Saksela, Vesa Kataja, Petri Bono, Jouni Junnila, Henrik Lindman
Summary: The study suggests that adding capecitabine to a chemotherapy regimen containing docetaxel, epirubicin, and cyclophosphamide can prolong the survival of patients with early breast cancer. Data shows that patients in the TX-CEX group had longer survival compared to those in the T-CEF group, especially for patients with estrogen receptor-negative and triple-negative cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
Jiong Wu, Zefei Jiang, Zhenzhen Liu, Benlong Yang, Hongjian Yang, Jinhai Tang, Kun Wang, Yunjiang Liu, Haibo Wang, Peifen Fu, Shuqun Zhang, Qiang Liu, Shusen Wang, Jian Huang, Chuan Wang, Shu Wang, Yongsheng Wang, Linlin Zhen, Xiaoyu Zhu, Fei Wu, Xiang Lin, Jianjun Zou
Summary: This study demonstrates that neoadjuvant pyrotinib, trastuzumab, and docetaxel significantly improve the total pathological complete response rate compared to placebo, trastuzumab, and docetaxel in patients with HER2-positive early or locally advanced breast cancer, with manageable toxicity. This provides a new option for the treatment of HER2-positive breast cancer.
Article
Genetics & Heredity
Wenxian Hu, Kezhen Lv, Rongyue Teng, Jida Chen, Chenpu Xu, Lidan Jin, Yongxia Chen, Wenhe Zhao
Summary: This retrospective study comparing PLD and epirubicin as adjuvant therapy for breast cancer found that PLD has similar anti-cancer efficacy as epirubicin while inducing lower levels of cardiac toxicity in Han Chinese population. The study suggests that PLD-based adjuvant chemotherapy could be a better option than epirubicin for breast cancer patients, especially those with existing cardiac diseases.
FRONTIERS IN GENETICS
(2021)
Article
Oncology
Ming Xie, Yan Zhong, Yide Yang, Fang Shen, Yue Nie
Summary: The study revealed that extended adjuvant endocrine therapy can improve disease-free survival, overall survival, relapse-free survival, distant metastatic-free survival, reduce the incidence of new breast cancer, but also increase the risk of bone fracture and osteoporosis.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Steven S. Fu, Alexander J. Rothman, David M. Vock, Bruce R. Lindgren, Daniel Almirall, Abbie Begnaud, Anne C. Melzer, Kelsey L. Schertz, Mariah Branson, David Haynes, Patrick Hammett, Anne M. Joseph
Summary: Adding a referral to prescription medication therapy management (MTM) to the tobacco longitudinal care (TLC) program showed positive effects among patients eligible for lung cancer screening (LCS) who did not respond to early treatment; however, decreasing the intensity of TLC among early treatment responders did not show significant improvement.
Article
Pharmacology & Pharmacy
Chen Zhu, Pan-pan Gan, Na-lin Sun, Li-qun Cao
Summary: This study evaluates the clinical efficacy of epirubicin plus docetaxel or paclitaxel in breast cancer patients. The combination of epirubicin and paclitaxel showed greater efficacy, improved safety profile, enhanced survival and recurrence control, and provided better quality of life compared to epirubicin plus docetaxel. Further large-scale and better-randomized clinical trials are needed to confirm these findings.
TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH
(2023)
Article
Urology & Nephrology
Nattakorn Dhiantravan, Louise Emmett, Anthony M. Joshua, David A. Pattison, Roslyn J. Francis, Scott Williams, Shahneen Sandhu, Ian D. Davis, Ian Vela, Nitika Neha, Mathias Bressel, Declan G. Murphy, Michael S. Hofman, Arun A. Azad
Summary: The study aims to evaluate the activity and safety of Lu-177-PSMA-617 in men with de novo metastatic hormone-naive prostate cancer.
Article
Oncology
E. E. Vokes, N. Ready, E. Felip, L. Horn, M. A. Burgio, S. J. Antonia, O. Aren Frontera, S. Gettinger, E. Holgado, D. Spigel, D. Waterhouse, M. Domine, M. Garassinoio, L. Q. M. Chow, G. Blumenschein, F. Barlesi, B. Coudert, J. Gainor, O. Arrieta, J. Brahmer, C. Butts, M. Steins, W. J. Geese, A. Li, D. Healey, L. Crino
ANNALS OF ONCOLOGY
(2018)
Article
Oncology
Corentin Richard, Jean-David Fumet, Sandy Chevrier, Valentin Derangere, Fanny Ledys, Aurelie Lagrange, Laure Favier, Bruno Coudert, Laurent Arnould, Caroline Truntzer, Romain Boidot, Francois Ghiringhelli
CLINICAL CANCER RESEARCH
(2019)
Correction
Oncology
Jean-David Fumet, Corentin Richard, Fanny Ledys, Quentin Klopfenstein, Philippe Joubert, Bertrand Routy, Caroline Truntzer, Andreanne Gagne, Marc-Andre Hamel, Camila Figueiredo Guimaraes, Bruno Coudert, Laurent Arnould, Laure Favier, Aurelie Lagrange, Sylvain Ladoire, Pierre Saintigny, Sandra Ortiz-Cuaran, Maurice Perol, Pascal Foucher, Paul Hofman, Marius Ilie, Sandy Chevrier, Romain Boidot, Valentin Derangere, Francois Ghiringhelli
BRITISH JOURNAL OF CANCER
(2019)
Article
Obstetrics & Gynecology
Aurelie Lagrange, Damien Decoux, Nathalie Briot, Audrey Hennequin, Bruno Coudert, Isabelle Desmoulins, Aurelie Bertaut
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
(2019)
Article
Oncology
Angeline Ginzac, Bertrand Barres, Marion Chanchou, Emilie Gadea, Ioana Molnar, Charles Merlin, Bruno Coudert, Emilie Thivat, Xavier Durando
Article
Oncology
C-G Kaderbhai, B. Coudert, A. Bertaut, J. Adnet, L. Favier, A. Lagrange, K. Peignaux-Casasnovas, L. Mettey, Z. Tharin, P. Foucher, E. Martin
CANCER RADIOTHERAPIE
(2020)
Article
Oncology
Sandra M. Swain, David Miles, Sung-Bae Kim, Young-Hyuck Im, Seock-Ah Im, Vladimir Semiglazov, Eva Ciruelos, Andreas Schneeweiss, Sherene Loi, Estefania Monturus, Emma Clark, Adam Knott, Eleonora Restuccia, Mark C. Benyunes, Javier Cortes
Article
Oncology
Sophie Frank, Matthieu Carton, Coraline Dubot, Mario Campone, Barbara Pistilli, Florence Dalenc, Audrey Mailliez, Christelle Levy, Veronique D'Hondt, Marc Debled, Thomas Vermeulin, Bruno Coudert, Christophe Perrin, Anthony Goncalves, Lionel Uwer, Jean-Marc Ferrero, Jean-Christophe Eymard, Thierry Petit, Marie-Ange Mouret-Reynier, Anne Patsouris, Tahar Guesmia, Thomas Bachelot, Mathieu Robain, Paul Cottu
Article
Oncology
Celia Vaury, Pauline Macaire, Francoise Goirand, Bruno Coudert, Pascal Guerard, Antonin Schmitt
Summary: This case demonstrates poor diffusion of everolimus in pleural fluid, leading to inefficacy in treating pleural progression of metastatic breast cancer.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2021)
Article
Oncology
Paul Cottu, Bruno Coudert, David Perol, Anne Doly, Julien Manson, Olivier Aujoulat, Hugues Barletta, Nassera Chalabi, Laurence Samelson, Xavier Pivot
EUROPEAN JOURNAL OF CANCER
(2020)
Article
Oncology
Sylvain Ladoire, Vincent Goussot, Emilie Redersdorff, Adele Cueff, Elise Ballot, Caroline Truntzer, Siavoshe Ayati, Leila Bengrine-Lefevre, Nathalie Bremaud, Bruno Coudert, Isabelle Desmoulins, Laure Favier, Clea Fraisse, Jean-David Fumet, Roxana Hanu, Audrey Hennequin, Alice Hervieu, Silvia Ilie, Coureche Kaderbhai, Aurelie Lagrange, Nils Martin, Irina Mazilu, Didier Mayeur, Remi Palmier, Anne-Laure Simonet-Lamm, Julie Vincent, Sylvie Zanetta, Laurent Arnould, Charles Coutant, Aurelie Bertaut, Francois Ghiringhelli
Summary: A study conducted at a large cancer center showed low seroprevalence of SARS-CoV-2 antibodies among both staff and patients, despite more high-risk factors among patients. None of the tested risk factors were statistically associated with seroprevalence in either group. Only fever, loss of smell, and loss of taste were significantly more frequent among seropositive patients.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Julie Niogret, Lorraine Dalens, Caroline Truntzer, Sandy Chevrier, Laure Favier, Aurelie Lagrange, Bruno Coudert, Clea Fraisse, Pascal Foucher, Ayoub Zouak, Virginie Westeel, Vincent Goussot, Valentin Derangere, Juliette Albuisson, Laurent Arnould, Romain Boidot, Coureche-Guillaume Kaderbhai, Francois Ghiringhelli
Summary: The study demonstrates the feasibility of integrating large Next Generation Sequencing (LNGS) into clinical management, but it does not appear to provide clinical benefit in the management of patients with advanced non-small-cell lung cancer (NSCLC).
Article
Medicine, General & Internal
Bruno Coudert, Jean-Yves Pierga, Marie-Ange Mouret-Reynier, Kaldoun Kerrou, Jean-Marc Ferrero, Thierry Petit, Fanny Le Du, Pierre-Francois Dupre, Thomas Bachelot, Philippe Gabelle, Marie-Pierre Chauvet, David Coeffic, Catherine Barbe, Jean-Briac Prevost, Gilles Paintaud, Gilles Thibault, Abdennour Ferhat, Julien Dupin, Alina Berriolo-Riedinger, Laurent Arnould
Article
Respiratory System
C. Fontaine-Delaruelle, J. Mazieres, J. Cadranel, B. Mastroianni, C. Dubos-Arvis, P. Dumont, I. Monnet, E. Pichon, M. Locatelli-Sanchez, A. Dixmier, B. Coudert, S. Fraboulet, P. Foucher, E. Dansin, N. Baize, M. Vincent, P. Missy, F. Morin, D. Moro-Sibilot, S. Couraud
RESPIRATORY MEDICINE AND RESEARCH
(2020)
Article
Cell Biology
Gaetan Chanteloup, Marine Cordonnier, Nicolas Isambert, Aurelie Bertaut, Alice Hervieu, Audrey Hennequin, Maxime Luu, Sylvie Zanetta, Bruno Coudert, Leila Bengrine, Isabelle Desmoulins, Laure Favier, Aurelie Lagrange, Pierre-Benoit Pages, Ivan Gutierrez, Jeanine Lherminier, Laure Avoscan, Clementine Jankowski, Cedric Rebe, Angelique Chevriaux, Marie-Martine Padeano, Charles Coutant, Sylvain Ladoire, Sylvain Causeret, Laurent Arnould, Celine Charon-Barra, Vanessa Cottet, Julie Blanc, Christine Binquet, Marc Bardou, Carmen Garrido, Jessica Gobbo
JOURNAL OF EXTRACELLULAR VESICLES
(2020)